Autoimmune diseases, affecting about 10% of the world's population, have been one of the hotspots in the field of drug research because of their complex pathogenesis. The treatments for autoimmune diseases mainly include traditional synthetic disease-modifying antirheumatic drugs (DMARDs) such as glucocorticoids, immunosuppressants, immunomodulators, and anti-inflammatory drugs, macromolecular monoclonal antibodies or their derivatives such as Infliximab and Tolizumab, and small molecule targeted DMARDs such as JAK inhibitors Tofacitinib and Baritinib. The treatment of these diseases usually takes months or even years. Thus, adverse drug reaction monitoring is very important, regardless of whether they are traditional DMARDs or new biological DMARDs. For their wide range of targets, good safety, and potential role in immune regulation, natural drugs such as curcumin, resveratrol, and colquhounia root have shown good potential in the treatment of autoimmune diseases in preclinical or clinical studies.
万方数据
